Thienopyridine NOX2 inhibitors

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof

wherein:

R1 is selected from the group consisting of:

H, halo, CN, (CH 2 ) n NRaRa, C(O)NRaRa, C(O)ORb, NRbC(O)Rb, (CH 2 ) m ORb,

C1-C6 alkyl optionally substituted with heterocycloalkyl,

heterocycloalkyl,

C1-C6 alkynyl optionally substituted with OH, C1-C3 alkoxy, NRaRa or heterocycloalkyl,

(CH 2 ) n Rc wherein Rc is optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, C1-C3 alkyl, NRaRa and halo, and

(CH 2 ) n Rd wherein Rd is optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, C1-C3 alkyl, NRaRa and halo;

R2 is selected from the group consisting of:

H, halo, CN, C(O)NRaRa,

C1-C6 alkyl,

heterocycloalkyl,

(CH 2 ) n Rc wherein Rc is optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, (CH 2 ) n NRaC(O)ORa, (CH 2 ) n NRaRa, halo, C1-C4 alkyl optionally substituted with one to three F, and heterocycloalkyl optionally substituted with C(O)ORb, and

(CH 2 ) n Rd wherein Rd is optionally substituted with one or more substituents selected from the group consisting of C1-C4 alkyl, C1-C3 alkoxy, halo, heterocycloalkyl and (CH 2 ) n NRaRa;

R3 is selected from the group consisting of:

C1-C6 alkyl optionally substituted with Rc wherein Rc is optionally substituted with halo,

heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of halo and C(O)ORb wherein Rb is optionally substituted with phenyl,

cycloalkyl,

Rc optionally substituted with one or more substituents selected from the group consisting of C1-C3 alkoxy, NRaRa, NO 2 , halo, and C1-C4 alkyl optionally substituted with one to three F, and

Rd optionally substituted with one or more substituents selected from the group consisting of C1-C4 alkyl, C1-C3 alkoxy, halo and phenyl;

R4 is H, C1-C6 alkyl, C1-C3 alkoxy, halo, or OH;

each Ra is H or C1-C6 alkyl or both Ra groups, independently in each instance, taken together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocycloalkyl ring;

each Rb is H or C1-C6 alkyl;

each Rc is phenyl;

each Rd is heteroaryl;

each m is 1 or 2; and

each n is 0, 1, 2 or 3.

2. A compound or salt according to claim 1 , wherein R1 is C1-C3 alkyl or H.

3. A compound or salt according to claim 1 , wherein R1 is pyrazolyl.

4. A compound or salt according to claim 1 , wherein R2 is phenyl substituted with one or more substituents selected from the group consisting of dimethylamino, F, pyrrolidinyl and morpholinyl.

5. A compound or salt according to claim 1 , wherein R2 is pyridinyl substituted with dimethylamino, pyrrolidinyl or morpholinyl.

6. A compound or salt according to claim 1 , wherein R3 is phenyl optionally substituted with one or more Cl or C1-C3 alkoxy.

7. A compound or salt according to claim 1 , wherein R3 is heteroaryl optionally substituted with C1-C4 alkyl.

8. A compound or salt according to claim 1 , wherein R4 is methyl or H.

9. A compound of Formula (I) or a salt thereof according to claim 1 , wherein the compound is selected from:

3-Chloro-N-{6-methyl-2-(1H-pyrazol-4-yl)-3-[3-(1-pyrrolidinyl)phenyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide (E105);

3-Chloro-N-{6-methyl-2-(1H-pyrazol-4-yl)-3-[5-(1-pyrrolidinyl)-3-pyridinyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide (E108);

3-Chloro-N-{6-methyl-3-[3-(1-pyrrolidinyl)phenyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide (E112);

N-{6-Methyl-2-(1H-pyrazol-4-yl)-3-[5-(1-pyrrolidinyl)-3-pyridinyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide (E113); and

N-{6-Methyl-2-(1H-pyrazol-4-yl)-3-[3-(1-pyrrolidinyl)phenyl]thieno[2,3-b]pyridin-4-yl}benzenesulfonamide (E114).

10. A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.